arrow
M

Mehmet Artaç

Necmettin Erbakan University
H指数:23
被引数:2,589

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The efficacy of nivolumab does not increase in current smokers with metastatic non-small cell lung cancer: multicenter, retrospective, and observational study

纳武利尤单抗在吸烟的转移性非小细胞肺癌患者中的疗效未增加:多中心、回顾性及观察性研究

2026-11-170
OA
Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy

局部晚期直肠癌患者接受总新辅助治疗后出现错配修复缺陷或微卫星不稳定性

2026-07-020
PRE
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

围手术期FLOT方案后复发性胃和胃食管结合部癌的一线治疗:土耳其肿瘤学组(TOG)多中心真实世界分析

2026-05-180
PRE
The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study

质子泵抑制剂对转移性非小细胞肺癌中纳武利尤单抗疗效的影响:一项多中心真实世界研究

2026-01-200
PRE
Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study

与健康相关的生活质量和免疫检查点抑制剂治疗长期存活者的心理社会结局:一项全国性多中心研究

2025-12-100
OA
The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study

靶向疗法在肺鳞状细胞癌转移中的疗效:一项土耳其肿瘤学组多中心研究

2025-12-010
PRE
Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study

瑞格非尼单抗与安慰剂联合铂类化疗在一线非鳞状或鳞状转移性非小细胞肺癌患者中的比较(POD1UM-304):一项三期、多区域、安慰剂对照、双盲、随机研究

2025-09-190
PRE
Integrating machine learning prediction and causal inference analysis to unravel determinants of progression in EGFR-mutant, advanced NSCLC

整合机器学习预测与因果推断分析,以揭示EGFR突变、晚期非小细胞肺癌进展的决定因素

2024-09-011
PRE
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

细胞周期蛋白依赖性激酶抑制剂后依维莫司加激素治疗的疗效; 现实生活经验,TOG研究

2024-08-090
PRE